Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia

British Journal of Haematology

Volumn 99, Issue 4, 1997, Pages 939-944

  Parker, J E ^a   Pagliuca, A ^a   Mijovic, A ^a   Cullis, J O ^a   Czepulkowski, B ^a   Rassam, S M B ^b   Samaratunga, I R ^c   Grace, R ^d   Gover, P A ^d   Mufti, G J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY S HOSPITAL   (United Kingdom)

^c Farnborough Hospital

^d EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

Autologous stem cell transplantation; FLAG idarubicin; Myelodysplastic syndrome; Therapy related MDS

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CYTOPENIA; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYELODYSPLASTIC SYNDROME; PAROTITIS; PRIORITY JOURNAL; RASH; RECURRENCE RISK; SENSORIMOTOR NEUROPATHY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 6844237007     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.4763281.x     Document Type: Article

References (34)

1. Anderlini, P., Benjamin, R.S., Wong, F.C., Kantarjian, H.M., Andreef, M., Kornblau, S.M., O'Brien, S., Mackay, B., Ewer, M.S., Pierce, S.A. & Estey, E.H. (1995) Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. Journal of Clinical Oncology, 13, 2827-2834.
2. Anderson, J.E., Appelbaum, F.R. & Storb, R. (1995) An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leukemia and Lymphoma, 17, 95-99.
3. Armitage, J.O., Dick, F.R., Needleman, S.W. & Burns, C.P. (1981) Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treatment Reports. 65, 601-605.
4. Aul, C. & Schneider, W. (1990) Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy? Hamatologie-Bluttransfusion, 33, 382-386.
5. Bhalla, K., Holladay, C., Arlin, Z., Grant, S., Ibrado, A.M. & Jasiok, M. (1991) Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood. 78, 2674-2679.
6. Boogaerts, M.A., Verhoef, G.E.G. & Demuynck, H. (1996) Treatment and prognostic factors in myelodysplastic syndromes. Baillieres Clinical Haematology, 9, 161-183.
7. Carella, A.M., Berman, E., Maraone, M.P. & Ganzina, F. (1990) Idarubicin in the treatment of acute leukemias: an overview of preclinical and clinical studies. Haematologica, 75, 159-169.
8. Chen, Z.M., Colombo, T., Conforti, L., Grazia-Donelli, M., Fiedorowicz, R.J., Marchi, S., Paolini, A., Riva, E., Zuanetti, G. & Latini, R. (1987) Effects of three new anthracyclines and doxorubicin on the rat isolated heart. Journal of Pharmacy and Pharmacology 39, 947-950.
9. Delforge, M., Demuynck, H., Vandenberghe, P., Verhoef, G., Zachee, P., van Duppen, V., Marijnen, P., Van den Berghe, H. & Boogaerts, M.A. (1995) Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with highrisk myelodysplastic syndromes. Blood, 86, 3660-3667.
10. Demuynck, H., Delforge, M., Verhoef, G.E., Zachee, P., Vandenberghe, P., Van den Berghe, H. & Boogaerts, M.A. (1996) Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. British Journal of Haematology, 92, 351-359.
11. De Witte, T., Muus, P., De Pauw, B. & Haanen, C. (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer, 66, 831-837.
12. De Witte, T., Suciu, S., Boogaerts, M., Labar, B., Archimbaud, E., Aul, C., Selleslag, D., Ferrant, A., Weijermans, P., Mandelli, F., Amadori, S., Jehn, U., Muus, P., DeMuynck, H., Dardenne, M., Willemze, R., Gratwohl, A. & Apperley, J. (1996) The influence of cytogenetic abnormalities on treatment outcome after intensive antileukemic therapy for patients with high risk MDS and AML following MDS. Blood, 88, (Suppl.1). 454a.
13. De Witte, T., Suciu, S., Peetermans, M., Fenaux, P., Strijckmans, P., Hayat, M., Jaksic, B., Selleslag, D., Zittoun, R., Dardenne, M., Solbu, G., Zwierzina, H. & Muus, P. (1995) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration: a pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia, 9, 1805-1811.
14. Dorr, R.T., Bozak, K.A., Shipp, N.G., Hendrix, M., Alberts, D.S. & Ahmann, F. (1988) In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios. Cancer Research, 48, 5222-5227.
15. Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L.E., Koller, C., Kornblau, S., Pierce, S., Friereich, E., Deisseroth, A. & Keating, M. (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Journal of Clinical Oncology, 12, 671-678.
16. Fenaux, P., Morel, P., Rose, C., Lai, J.L., Jouet, J.P. & Bauters, F. (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. British Journal of Haematology, 77, 497-501.
17. Gandhi, V., Estey, E., Keating, M.J. & Plunkett, W. (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. Journal of Clinical Oncology, 11, 116-124.
18. Gajewski, J.L., Ho, W.G., Nimer, S.D., Hirji, K.F., Gekeiman, L., Jacobs, A.D. & Champlin, R.E. (1989) Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. Journal of Clinical Oncology, 7, 1637-1645.
19. Goto, H., Shimazaki, C., Hirata, T., Ashihara, E., Ohkawa, K., Oku, N., Inaba, T., Fujita, N. & Nakagawa, M. (1993) Recombinant human granulocyte colony-stimulating factor in combination with continuous infusion of cytosine arabinoside for the treatment of refractory acute myelogenous leukemia. Acta Haematologica, 89, 144-148.
20. Greenberg, P., Cox, C., Le Beau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vellespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
21. Hirst, W.J. & Mufti, G.J. (1994) The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromes. Leukemia Research, 18, 797-804.
22. Hoyle, C.F. de-Bastos, M., Wheatley, K., Sherrington, P.D., Fischer, P.J., Rees, J.K., Gray, R. & Hayhoe, F.G. (1989) AML associated with previous cytotoxic therapy. MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. British Journal of Haematology, 72, 45-53.
23. Koistinen, P., Wang, C., Yang, G.S., Wang, Y.F., Williams, D.E., Lyman, S.D., Minden, M.D. & MeCulloch, E.A. (1991) OCI/AML-4 an acute myeloblastic leukemia cell line: regulation and response to cytosine arabinoside. Leukemia, 5, 704-711.
24. Maung, Z.T., Wood, A.C., Jackson, G.H., Turner, G.E., Appleton, A.L. & Hamilton, P.J. (1994) Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia. British Journal of Haematology, 88, 649-655.
25. Mertelsmann, R., Tzvi-Thaler, H., To, L., Gee, T.S., McKenzie, S., Schauer, P., Friedman, A., Arlin, Z., Cirrincione, C. & Clarkson, B. (1980) Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood, 56, 773-781.
26. Michels, S.D., Saumur, J., Arthur, D.C., Robison, L.L. & Brunning, R.D. (1989) Refractory anemia with excess of blasts in transformation: hematologic and clinical study of 52 patients. Cancer. 64, 2340-2346.
27. Milroy, R., Cummings, J., Kaye, S.B. & Banham, S.W. (1987) Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer. Cancer Chemotherapy and Pharmacology, 20, 75-77.
28. Ohno, R., Tomonaga, M., Kobayashi, T., Kanamaru, A., Shirakawa, S., Masaoka, T., Omine, M., Oh, H., Nomura, T., Sakai, Y., Hirano, M., Yokomaku, S., Nakayuma, S., Yoshida, Y., Miura, A.B., Morishima, Y., Dony, H., Nino, Y., Hamajima, N. & Takaku, F. (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. New England Journal of Medicine, 323, 871-877.
29. Preisler, H.D., Raza, A., Barcos, M., Azarnia, N., Larson, R., Browman, G., Walker, I., Grunwald, H., D'Arrigo, P., Stein, A., Bloom, M., Goldberg, J., Gottlieb, A., Bennett, J., Kirshner, J. & Priore, R. (1986) High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study. American Journal of Hematology, 23, 131-134.
30. Richard, C., Iriondo, A., Garijo, J., Baro, J., Conde, E., Recio, M., Cuadrado, M.A., Bello, C. & Zubizarreta. A. (1989) Therapy of advanced myelodysplastic syndrome with aggressive chemotherapy. Oncology, 46, 6-9.
31. Ross, D.D., Doyle, L.A., Yang, W., Tong, Y. & Cornblatt, B. (1995) Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochemical Pharmacology. 50, 1673-1683.
32. Tafuri, A. & Andreeff, M. (1990) Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia, 4, 826-834.
33. Tosi, P., Visani, G., Ottaviani, E., Manfori, S., Zinzani, P.L. & Tura, S. (1994) Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia, 8, 2076-2082.
34. Tricot, G. & Boogaerts, M.A. (1986) The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. British Journal of Haematology, 63, 477-483.